Amylyx Surges 56% After Phase 3 Drug Cuts Hypoglycemia Events 55%
Updated
Updated · Yahoo Finance · Aug 18
Amylyx Surges 56% After Phase 3 Drug Cuts Hypoglycemia Events 55%
3 articles · Updated · Yahoo Finance · Aug 18
Summary
Amylyx shares jumped 56% to $32.26 after avexitide hit both primary and secondary endpoints in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia.
In 78 patients after Roux-en-Y gastric bypass, the drug reduced severe hypoglycemic events 55% versus placebo—beating the 35% regulatory bar and the 50% benefit level physicians view as clinically meaningful.
Amylyx said avexitide showed a clean safety profile, with no treatment-related serious adverse events; diarrhea and injection-site reactions were the most common side effects.
The candidate targets a condition affecting about 160,000 U.S. patients and has no FDA-approved treatments; Amylyx plans to file for approval by end-2026 and aims for a 2027 launch if cleared.